Mounjaro (Tirzepatide): A Review

Abstract

Mounjaro (tirzepatide) injection is Food and Drug Administration approved as an alternate supplement for diet and exercise to improve insulinemic control in adults with type 2 diabetes mellitus. It is the first and only uni-molecular dual receptor agonist. Hormones such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 is involved in the blood sugar control. Food and Drug Administration introduces mounjaro as a new class of medication for people with type II diabetes in the year 2022. Precautions to be monitored for lactating mothers, kidney, and pancreas problems, using birth pills and so on. Contraindications are thyroid carcinoma and severe allergic reactions. The dosage is available from 2.5-15 mg/ 0.5 ml, store at 36⁰F to 46⁰F (2⁰C to 8⁰C). MOA Mounjaro is a single molecule that selectively binds to the receptors of GIP and GLP-1 to target GIP and GLP-1 hormones. Side effects such as, qualmishness, loose stools, food aversion, bloating abdomen and so on.